The seminar will mainly focus on critical points related to clinical trials.
Among the others, a critical point is related to the clinical trial endpoints, other than survival, that objectively demonstrate meaningful clinical benefit. In fact, with the introduction of molecular pathology, patients and their oncologists now deal with a greater variety of malignant diseases than ever before, each of which likely benefits from a unique approach to treatment. Furthermore, many new drugs determine slow tumor progression instead of causing tumor shrinkage. Therefore cancer drug trials may require more patients and the more frequent use of placebo controls, thus presenting greater recruitment challenges as well as requiring a long period of time to reach major clinical endpoints, more expensive clinical documentation to record progression events, and additional regulatory scrutiny.
For all the mentioned reasons potential surrogate endpoints and other biomarkers have been identified and evaluated and they will be discussed during the seminar.
Another critical point is related to the clinical trial conduction within the sites. Therefore it is also important to know what deviations, violations and exceptions represent and when they could have an impact on the clinical trial results. On the other hand, it is important to underline in which situations a waiver could be given and a less strict Company’s behavior could facilitate the study without compromising the study results.
Why should you attend?
More than 80% of drugs for all indications entering clinical development do not get marketing approval, with many failing late in development often in Phase III trials, because of unexpected safety issues or difficulty determining efficacy, including confounded outcomes. Many factors may be involved in this low success rate: among the others, the limited knowledge of the determinants of drug sensitivity and resistance; heterogeneous patient populations and lack of biomarkers to identify patients most likely to benefit from specific treatments; the design of the clinical trials, which are often made on the basis of the “traditional statistical” requirements; the lack of agreement among clinicians, investigators, and regulators as to what constitutes clinical benefit in some circumstances.
Furthermore, several agents that obtain the approval are criticized by Medical Oncologists. In fact, regardless of approval, phase III trials with new drugs may presents some criticism that could lead on one hand to delay or limitation in the approval and on the other hand on a limited belief in the drug within Medical Oncologists. This may cause a reduced prescription of the drug, despite its real activity and efficacy.
This seminar will provide valuable assistance to Companies, CROs, Investors and Professionals, including Physicians and Payers. Those that would benefit most would be:
Lecture 1: Targeted “herapies in Medical Oncology – big killers
Lecture 2: Targeted therapies in Medical Oncology – rare tumors
Lecture 3: Traditional statistical design of clinical trials in Oncology
Lecture 4: New clinical trials design in Oncology
Lecture 5: Q & A
Lecture 1: Requirements of regulatory authorities
Lecture 2: New endpoints, impact of deviation, violation and exception on clinical trials
Lecture 3: Critical analysis of phase III trials – part 1
Lecture 4: Critical analysis of phase III trials ‘ part 2
Send this to a friend